Tuesday, December 8, 2015
CWWeekly presents this feature as a way to put the spotlight on issues faced by executives in the clinical trial space. Staff Writer Ron Rosenberg spoke to Noah Craft, M.D., Ph.D., co-founder of Los Angeles-based Science 37, which seeks to transform biomedical discovery and reduce clinical trial costs using a mobile research platform to simplify the process of participating in clinical studies.
The number of small, pilot clinical trials to evaluate new wearable devices continues to grow, as the once-untested technology is becoming another research tool for companies focused on developing new sensors for both handheld and wearable products.
AltheaDx, a San Diego-based commercial stage molecular diagnostics company, has launched a CLIA-validated, next-generation sequencing (NGS) assay, AltheaDx Oncology Panel (AOP50), designed for multiple drug and companion diagnostic development programs.
hVIVO, a U.K.-based provider of human disease models, and Everbridge, a global provider of SaaS-based unified critical communications solutions, are joining forces to offer a next-generation, virtual clinical trial platform that has the potential to transform the trial volunteer experience.
Qlik, a Radnor, Pa.-based visual analytics provider, is integrating its mobile visual analytical applications with Veeva CRM Mobile for self-service data discovery and user-driven guided analytics as the newest initiative in its partnership with Veeva Systems, a cloud-based software provider for the global life sciences industry.
Princeton, N.J.-based Certara, a global biosimulation technology-enabled drug development company, has acquired XenologiQ, a quantitative systems pharmacology (QSP) consultancy that maintains its headquarters in the U.K. [Read More]
San Diego’s Human Longevity Inc. (HLI), a genomics-based, technology-driven company, has acquired Cypher Genomics, a genome informatics company offering human genomic interpretation software solutions. The company has 14 employees who will join HLI, including Cypher CEO and co-founder Ashley Van Zeeland, Ph.D., who now is the head of HLI’s pediatric business. Financial details of the deal were not disclosed.
CWWeekly presents this feature as a way to put the spotlight on issues faced by executives in the clinical trials space. Staff Writer Ron Rosenberg spoke with Ray Dorsey, M.D., David M. Levy Professor of Neurology and director of the Center for Human Experimental Therapeutics (CHET) at the University of Rochester Medical Center.